🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
GILD
NASDAQ
🇺🇸 US
Gilead Sciences, Inc.
Pharmaceuticals
31Score
DipBuster Score™
$133.21
$1.07 (-0.8%)
Live price · Source: Yahoo
52-Week Position
$107.75
51% of range
$157.29
Beta
0.343
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.343
52W High$157.29
52W Low$107.75
DipBuster Brief
Key signals at a glance
Zone: Hold / Watch
Neutral
Mid-Range Position (51% of 52-Week Range)
The stock sits in the middle of its annual range — no extreme dip opportunity, but also not overextended.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position51% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.343
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Gilead Sciences, Inc. (GILD), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-07-01 | O'day Daniel Patrick | SELL | 3,100 |
| 2026-07-01 | O'day Daniel Patrick | SELL | 11,900 |
| 2026-06-15 | Mercier Johanna | SELL | 450 |
| 2026-06-15 | Mercier Johanna | SELL | 1,070 |
| 2026-06-15 | Mercier Johanna | SELL | 1,480 |
| 2026-06-15 | Dickinson Andrew D | SELL | 3,000 |
| 2026-06-10 | Cain Wettan Keeley M | SELL | 589 |
| 2026-06-10 | Cain Wettan Keeley M | SELL | 283 |
| 2026-06-10 | Cain Wettan Keeley M | BUY | 589 |
| 2026-06-10 | Mercier Johanna | SELL | 2,796 |
Valuation
P/E RatioN/A
Market CapN/A
Beta0.343
Dividend/yrNone
52W High$157.29
52W Low$107.75
52-Week Range
$107.75Now$157.29
51% through annual range
From 52W High−15.3%
From 52W Low+23.6%
📖 Plain English Summary
Gilead Sciences, Inc. is at 51% of its 52-week range. Beta 0.343 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for GILD
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — GILD
Heuristic · balance sheet, insider filings, price data, academic research
Gilead Sciences, Inc. — DipBuster Score 31/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Gilead Sciences, Inc. free
Add GILD to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
19/25
Momentum & Volume
7/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
5
/100 · NEUTRAL
dip depth
5/25
oversold rsi
1/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 31/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializi…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Daniel O'Day
Staff
17,000 employees
Website